An Investigation of the Information Seeking Behavior of Medical Oncologists in Metropolitan Pittsburgh Using a Multimethod Approach

di Lomax, Edward C., Lowe, Henry J., Logan, Theodore F.
Pubblicazione 1997

CCR7 and CCR9 together recruit hematopoietic progenitors to the adult thymus

di Zlotoff, Daniel A., Sambandam, Arivazhagan, Logan, Theodore D., Bell, J. Jeremiah, Schwarz, Benjamin A., Bhandoola, Avinash
Pubblicazione 2010

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing...

di Bruce, Justine Yang, Eickhoff, Jens, Pili, Roberto, Logan, Theodore, Carducci, Michael, Arnott, Jamie, Treston, Anthony, Wilding, George, Liu, Glenn
Pubblicazione 2010

Delivery of progenitors to the thymus limits T-lineage reconstitution after bone marrow transplantation

di Zlotoff, Daniel A., Zhang, Shirley L., De Obaldia, Maria Elena, Hess, Paul R., Todd, Sarah P., Logan, Theodore D., Bhandoola, Avinash
Pubblicazione 2011

Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003

di Dudek, Arkadiusz Z., Liu, Li C., Gupta, Shilpa, Logan, Theodore F., Singer, Eric A., Joshi, Monika, Zakharia, Yousef N., Lang, Joshua M., Schwarz, James K., Al-Janadi, Anas, Alva, Ajjai S.
Pubblicato in J Clin Oncol (2020)

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

di Clark, Joseph I., Singh, Jatinder, Ernstoff, Marc S., Lao, Christopher D., Flaherty, Lawrence E., Logan, Theodore F., Curti, Brendan, Agarwala, Sanjiv S., Taback, Bret, Cranmer, Lee, Lutzky, Jose, Luna, Theresa L., Aung, Sandra, Lawson, David H.
Pubblicato in J Immunother Cancer (2018)

Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma

di Lam, Elaine T., Wong, Michael K. K., Agarwal, Neeraj, Redman, Bruce G., Logan, Theodore, Gao, Dexiang, Flaig, Thomas W., Lewis, Karl, Poust, Jamie, Monk, Paul, Jarkowski, Anthony, Sendilnathan, Arun, Bolden, Marcus, Kuzel, Timothy M., Olencki, Thomas
Pubblicazione 2014

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2

di Clark, Joseph I, Curti, Brendan, Davis, Elizabeth J, Kaufman, Howard, Amin, Asim, Alva, Ajjai, Logan, Theodore F, Hauke, Ralph, Miletello, Gerald P, Vaishampayan, Ulka, Johnson, Douglas B, White, Richard L, Wiernik, Peter H, Dutcher, Janice P
Pubblicato in J Investig Med (2021)

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM(SM) registry

di Curti, Brendan, Daniels, Gregory A., McDermott, David F., Clark, Joseph I., Kaufman, Howard L., Logan, Theodore F., Singh, Jatinder, Kaur, Meenu, Luna, Theresa L., Gregory, Nancy, Morse, Michael A., Wong, Michael K. K., Dutcher, Janice P.
Pubblicato in J Immunother Cancer (2017)

A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (procliv...

di Clark, Joseph, Flaherty, Lawrence, Ernstoff, Marc, Koon, Henry, Milhem, Mohammed, Militello, Gerald, Agarwala, Sanjiv, Curti, Brendan, Cranmer, Lee, Lao, Christopher D, Logan, Theodore F, Lutzky, Jose, Rudrapatna, Venkatesh, Daniels, Gregory, Taback, Bret, Aung, Sandra, Lowder, James, Lawson, David
Pubblicato in J Immunother Cancer (2014)

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

di Ribas, Antoni, Chesney, Jason A, Gordon, Michael S, Abernethy, Amy P, Logan, Theodore F, Lawson, David H, Chmielowksi, Bartosz, Glaspy, John A, Lewis, Karl, Huang, Bo, Wang, Erjian, Hsyu, Poe-Hirr, Gomez-Navarro, Jesus, Gerhardt, Diana, Marshall, Margaret A, Gonzalez, Rene
Pubblicazione 2012

NCI 8628 - A Randomized Phase II Study of Ziv-aflibercept and High Dose Interleukin-2 (HD IL-2) or HD IL-2 Alone for Inoperable Stage III or IV Melanoma

di Tarhini, Ahmad A., Frankel, Paul, Ruel, Christopher, Ernstoff, Marc S., Kuzel, Timothy M., Logan, Theodore F., Khushalani, Nikhil I., Tawbi, Hussein A., Margolin, Kim A., Awasthi, Sanjay, Butterfield, Lisa H., McDermott, David, Chen, Alice, Lara, Primo N., Kirkwood, John M.
Pubblicato in Cancer (2018)

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma

di Timmerman, John, Herbaux, Charles, Ribrag, Vincent, Zelenetz, Andrew D., Houot, Roch, Neelapu, Sattva S., Logan, Theodore, Lossos, Izidore S., Urba, Walter, Salles, Gilles, Ramchandren, Radhakrishnan, Jacobson, Caron, Godwin, John, Carpio, Cecilia, Lathers, Deanne, Liu, Yali, Neely, Jaclyn, Suryawanshi, Satyendra, Koguchi, Yoshinobu, Levy, Ronald
Pubblicato in Am J Hematol (2020)

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

di Weber, Jeffrey S, Gibney, Geoff, Sullivan, Ryan J, Sosman, Jeffrey A, Slingluff, Craig L, Lawrence, Donald P, Logan, Theodore F, Schuchter, Lynn M, Nair, Suresh, Fecher, Leslie, Buchbinder, Elizabeth I, Berghorn, Elmer, Ruisi, Mary, Kong, George, Jiang, Joel, Horak, Christine, Hodi, F Stephen
Pubblicato in Lancet Oncol (2016)

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advance...

di Chesney, Jason, Puzanov, Igor, Collichio, Frances, Singh, Parminder, Milhem, Mohammed M., Glaspy, John, Hamid, Omid, Ross, Merrick, Friedlander, Philip, Garbe, Claus, Logan, Theodore F., Hauschild, Axel, Lebbé, Celeste, Chen, Lisa, Kim, Jenny J., Gansert, Jennifer, Andtbacka, Robert H.I., Kaufman, Howard L.
Pubblicato in J Clin Oncol (2018)

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

di Motzer, Robert J., Rini, Brian I., McDermott, David F., Redman, Bruce G., Kuzel, Timothy M., Harrison, Michael R., Vaishampayan, Ulka N., Drabkin, Harry A., George, Saby, Logan, Theodore F., Margolin, Kim A., Plimack, Elizabeth R., Lambert, Alexandre M., Waxman, Ian M., Hammers, Hans J.
Pubblicato in J Clin Oncol (2015)

Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase...

di Amin, Asim, Dudek, Arkadiusz Z, Logan, Theodore F, Lance, Raymond S, Holzbeierlein, Jeffrey M, Knox, Jennifer J, Master, Viraj A, Pal, Sumanta K, Miller, Wilson H, Karsh, Lawrence I, Tcherepanova, Irina Y, DeBenedette, Mark A, Williams, W Lee, Plessinger, Douglas C, Nicolette, Charles A, Figlin, Robert A
Pubblicato in J Immunother Cancer (2015)

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in advanced clear cell renal cell carcinoma

di Voss, Martin H., Bhatt, Rupal S., Vogelzang, Nicholas J., Fishman, Mayer, Alter, Robert S., Rini, Brian I., Beck, J. Thaddeus, Joshi, Monika, Hauke, Ralph, Atkins, Michael B., Burgess, Earle, Logan, Theodore F., Shaffer, David, Parikh, Rahul, Moazzam, Nauman, Zhang, Xiaosha, Glasser, Chad, Sherman, Matthew L., Plimack, Elizabeth R.
Pubblicato in Cancer (2019)

Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

di Armstrong, Andrew J, Halabi, Susan, Eisen, Tim, Broderick, Samuel, Stadler, Walter M, Jones, Robert J, Garcia, Jorge A, Vaishampayan, Ulka N, Picus, Joel, Hawkins, Robert E, Hainsworth, John D, Kollmannsberger, Christian K, Logan, Theodore F, Puzanov, Igor, Pickering, Lisa M, Ryan, Christopher W, Protheroe, Andrew, Lusk, Christine M, Oberg, Sadie, George, Daniel J
Pubblicato in Lancet Oncol (2016)

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

di Alva, Ajjai, Daniels, Gregory A., Wong, Michael K. K., Kaufman, Howard L., Morse, Michael A., McDermott, David F., Clark, Joseph I., Agarwala, Sanjiv S., Miletello, Gerald, Logan, Theodore F., Hauke, Ralph J., Curti, Brendan, Kirkwood, John M., Gonzalez, Rene, Amin, Asim, Fishman, Mayer, Agarwal, Neeraj, Lowder, James N., Hua, Hong, Aung, Sandra, Dutcher, Janice P.
Pubblicato in Cancer Immunol Immunother (2016)